Q3 Earnings Estimate for TARS Issued By HC Wainwright

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Tarsus Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 5th. HC Wainwright analyst M. Caufield expects that the company will post earnings of $0.18 per share for the quarter. HC Wainwright has a “Buy” rating and a $88.00 price target on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ FY2027 earnings at $2.90 EPS, FY2028 earnings at $4.26 EPS and FY2029 earnings at $5.87 EPS.

Several other brokerages also recently issued reports on TARS. Zacks Research upgraded Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Guggenheim lifted their price objective on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a research report on Wednesday. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $69.83.

Tarsus Pharmaceuticals Price Performance

Shares of TARS stock opened at $68.20 on Thursday. The stock’s fifty day simple moving average is $62.37 and its 200 day simple moving average is $50.97. The company has a debt-to-equity ratio of 0.22, a current ratio of 5.26 and a quick ratio of 5.21. Tarsus Pharmaceuticals has a one year low of $38.51 and a one year high of $76.81. The firm has a market cap of $2.88 billion, a price-to-earnings ratio of -33.76 and a beta of 0.82.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. The business had revenue of $118.70 million for the quarter, compared to analyst estimates of $114.22 million. Tarsus Pharmaceuticals had a negative return on equity of 27.07% and a negative net margin of 22.17%.

Insider Transactions at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total value of $332,220.00. Following the completion of the sale, the chief executive officer owned 812,106 shares in the company, valued at approximately $44,966,309.22. This represents a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director William J. Phd Link sold 27,116 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $57.00, for a total value of $1,545,612.00. Following the completion of the sale, the director owned 143,332 shares of the company’s stock, valued at $8,169,924. This represents a 15.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 39,116 shares of company stock valued at $2,177,832 in the last quarter. 8.97% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Amalgamated Bank grew its stake in Tarsus Pharmaceuticals by 30.1% in the first quarter. Amalgamated Bank now owns 1,274 shares of the company’s stock valued at $65,000 after acquiring an additional 295 shares during the period. Allianz Asset Management GmbH acquired a new position in Tarsus Pharmaceuticals in the second quarter valued at about $227,000. Strs Ohio acquired a new position in Tarsus Pharmaceuticals in the first quarter valued at about $288,000. Adage Capital Partners GP L.L.C. acquired a new position in Tarsus Pharmaceuticals in the first quarter valued at about $26,199,000. Finally, Vanguard Group Inc. grew its stake in Tarsus Pharmaceuticals by 5.3% in the first quarter. Vanguard Group Inc. now owns 2,226,595 shares of the company’s stock valued at $114,380,000 after acquiring an additional 111,433 shares during the period. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.